JAGADISH PUPPALA
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease GRAPEVINE, TX NPI 1841292489
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease TX Novo Nordisk AS All categories
General Payments — all program years on this page
$592.37
- Category: General Payments
- Program years: PY2018–2023
- Record count: 29
- As of (CMS publication): 2026-01-23
Latest program year (PY2023): $205.52 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2023) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $205.52 | 7 |
By paying entity
Latest program year (PY2023) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $93.36 | 1 |
| Merck Sharp & Dohme Corporation | $55.43 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $20.16 | 1 |
| PFIZER INC. | $18.51 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $18.06 | 1 |
By program year
Records — PY2023 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1003158131 | Novo Nordisk Inc | $93.36 | 11/29/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1022535537 | Boston Scientific Corporation | $20.16 | 06/13/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1048393471 | Merck Sharp & Dohme LLC | $19.59 | 06/01/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1048393475 | Merck Sharp & Dohme LLC | $20.19 | 08/31/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1048867109 | Merck Sharp & Dohme LLC | $15.65 | 02/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1049940201 | PFIZER INC. | $18.51 | 06/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 992826925 | Novartis Pharmaceuticals Corporation | $18.06 | 06/22/2023 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.